The latest findings from the largest European project in the science of wastewater analysis are released today in Wastewater analysis and drugs — a European multi-city study (EMCDDA)
Archives for 2023
Bibliography: All Publications
Shooting Up: infections among people who inject drugs in the UK
This report describes the extent of infections and injecting-related harms among people who inject drugs (PWID) in the United Kingdom (UK Health Security Agency)
Global Report on Cocaine 2023
UNODC
Interim monitoring report on statutory funded residential rehabilitation placements
Placements approved by Alcohol and Drug Partnerships between 1 April 2021 and 31 December 2022 (Public Health Scotland)
The death penalty for drug offences: global overview 2022
This report, our twelfth on the subject, continues our work of providing regular updates on legislative, policy and practical developments related to the use of capital punishment for drug offences, a practice which is a clear violation of international standards (Harm Reduction International)
Substance misuse treatment in secure settings: 2021 to 2022
Statistics for alcohol and drug misuse treatment in prisons and other secure settings from the National Drug Treatment Monitoring System (NDTMS)
Report 18 of the National Wastewater Drug Monitoring Program
Report 18 of the National Wastewater Drug Monitoring Program covered sampling in August and October 2022. In August, 58 wastewater sites were monitored nationally, covering approximately 57% of the Australian population Download report
Global launch of the Annual Report 2022
INCB
Peer naloxone supply project
An evaluation of three pilot areas,(SDF)
Women and drugs: health and social responses
This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social responses for women who use drugs, and reviews the availability and effectiveness of the responses (EMCDDA)
Drug and Alcohol Treatment and Recovery Workforce Programme
This programme aims to transform the lives of those affected by drug and alcohol misuse by improving the quality and capacity of the drug and alcohol treatment and recovery workforce (NHS Health Education England)
Publication of ACMD’s review on nitrous oxide
The Advisory Council on the Misuse of Drugs (ACMD) has today (6 March 2023) published an updated harms assessment of nitrous oxide
Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms
Framework for action for integrated care boards (ICBs) and primary care (NHS England)
Monitoring Data Report 2022
Together with more than one hundred organizations and individuals from thirty-four European countries, C-EHRN set up for itself the task to provide an in-depth look at Harm Reduction in Europe – download report
Taking the initiative: how England is eliminating hepatitis C
This report explores the development of the programme, how several of the key initiatives have worked and developed over time, and next steps in the programme (HCV Action)
Youth Risk Behavior Survey Data Summary & Trends Report: 2011–2021
Provides the most recent surveillance data, as well as 10-year trends, on health behaviours and experiences among high school students in the United States (U.S.) related to adolescent health and well-being (CDC)
New EMCDDA work programme prepares agency for significant changes ahead
the latest EMCDDA work programme, which outlines our activities for 2023–2025
How England is eliminating hepatitis C
This report explores the development of the programme, how several of the key initiatives have worked and developed over time, and next steps in the programme (HCV Action)
Synthetic opioids will be banned as government acts to stop drug deaths
Eleven more lethal substances to be made Class A drugs, following a recommendation by the Advisory Council on the Misuse of Drugs (Home Office)
Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions (Australian Government)
